Revolution Medicines
RVMD
139 hedge funds and large institutions have $2.99B invested in Revolution Medicines in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 24 closing their positions.
88% more call options, than puts
Call options by funds: $5.09M | Put options by funds: $2.71M
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
28% more capital invested
Capital invested by funds: $2.34B → $2.99B (+$651M)
1.36% more ownership
Funds ownership: 103.95% → 105.32% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
9% less funds holding
Funds holding: 152 → 139 (-13)
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$45.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$31.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$23.7M |
| 4 |
DM
Deerfield Management
New York
|
+$22.6M |
| 5 |
BlackRock
New York
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$49.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$17.7M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$12.3M |
| 4 |
Goldman Sachs
New York
|
-$10.8M |
| 5 |
MGB
Mass General Brigham
Somerville,
Massachusetts
|
-$7.33M |
RVMD Hedge Fund Activity: Q2 2023 in Review
139 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q2 2023, worth a combined $2.99B — up 28% from $2.34B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of RVMD and 12 opened new positions — a net loss of 12 holders — while 42 trimmed existing stakes and 57 added.
The largest buyer was EcoR1 Capital, adding an estimated $45.3M. The largest seller was Column Group, cutting an estimated $49.1M.
- 139 institutional investors held Revolution Medicines (RVMD) as of Q2 2023, down from 152 in Q1 2023.
- Funds reported $2.99B of Revolution Medicines stock for Q2 2023, up 28% quarter-over-quarter.
- 12 funds opened new Revolution Medicines positions in Q2 2023 and 24 closed out, a net change of -12 holders.
- The largest Revolution Medicines buyer in Q2 2023 was EcoR1 Capital, an estimated $45.3M added.
- The largest Revolution Medicines seller in Q2 2023 was Column Group, an estimated $49.1M sold.
Based on aggregated 13F filings for Q2 2023.